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McCune-Albright syndrome (MAS) described in 1937 by Donovan James McCune and Fuller Albright [1,2]. MAS occurs in 1 in 100,000 to 1 in 1,000,000 people 
worldwide. The classical triad of MAS consists of polyostotic 
fibrous dysplasia (PFD), skin hyperpigmentation (cafe-au-lait 
spots), and endocrine dysfunctions [3]. Any combination of two 
or more of these typical findings constitutes MAS. Patients with 
MAS display mosaicism of activating somatic mutations of the 
gene encoding the alpha-subunit of Gs (GNAS1) [4]. Fibrous 
dysplasia (FD) lesions are typically found in the long bones of 
the extremities, rarely found in the hands, feet, or spine [5-8], 
ranging from asymptomatic lesions to the one causing marked 
disfigurement of the skull and spine [9]. Involvement of the skull 
can be particularly problematic, with lesions of the orbit resulting 
in visual loss or proptosis and lesions of the ear resulting in 
deafness and vertigo.
The café-au-lait spots are one of the most obvious signs of 
MAS and present as single or multiple tan-brown hyperpigmented 
flat macules with irregular (“coast of Maine”) borders developing 
during infancy and becoming even more obvious with age or 
with sun exposure [1]. The most common form of autonomous 
endocrine hyperfunction in this syndrome is gonadotropin-
independent precocious puberty. However, the non-endocrine 
abnormalities include chronic liver disease, tachycardia, and 
rarely sudden death, possibly from cardiac arrhythmias.
CASE REPORT
A 5-year-old Asian boy presented to pediatric ED with acute 
exacerbation of asthma which was managed as per hospital 
protocol. On examination, he was noted to have multiple café au lait 
spots across the left side of his body affecting his chest and back 
and left upper limb (Fig. 1). According to parents, these features 
have been present since he was a young baby. Previously, he was 
reviewed by a dermatologist at approximately 8 months of age 
and diagnosed as having eczema, leading to post-inflammatory 
skin infiltrates which were treated with emollients and steroid 
ointments with not much benefit. During this admission, he had a 
chest X-ray done to further investigate his respiratory illness, in 
which an incidental finding of a lytic lesion in the left humerus 
(Fig. 2) was noticed.
On physical examination, his weight was 15.3 kg (just above 
the 10th centile) and his height was 105 cm (above 25th centile 
for his age) and approximately at the mid-parental percentile 
for his family height. In view of café au lait macules and lytic 
bone lesions, a diagnosis of MAS was considered, and a battery 
of endocrine investigations was performed. An endocrinologist 
opinion was also assisted, and genetic testing for GNAS gene was 
done which showed no evidence of mosaicism.
Blood investigations revealed the following results: Glucose: 
4.8(3.9–7.8) mmol/L, hemoglobin A1c (HbA1c):HbA1c 
IFCC: 31 (19–40) mmol/mol and HbA1c DCCT derived: 5.0% 
(3.9–5.8%), CRP: <5 (0–5 mg/dl), calcium: 2.51 (2.20–2.70) 
mmol/L, phosphorus: 1.11 (1.05–1.80) mmol/L, liver profile: 
Normal, creatinine: 35(23–37) µmol/L, thyroid profile: T4 16.2 
(12–22) pmol/L, TSH 4.80 (0.27–4.20), thyroid peroxidase Ab: 
<4 IU/ml(Negative), growth hormone (GH) (random): 0.3 ng/ml, 
IGF-1: 8.3 (5.8–29.5) nmol/L, testosterone: <0.1 (0.1–1.1) nmol/L, 
prolactin: 7.29 (4–15.2) ng/ml, FSH: Lo 0.71 (1.5–12.4) mIU/ml, 
and LH levels were low: <0.10 (1.7-8.6) mIU/ml.
X-ray chest/skeletal survey reported FD of proximal left 
humerus, outer aspect of left clavicle, and also in the scapula 
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adjacent to the lower border of globoid fossa. According to the 
criteria, the diagnosis of MAS was confirmed. At present, as the 
child has no associated endocrinal abnormalities, he was kept 
under follow-up to have a close eye on his growth and to detect 
early any associated endocrinal dysfunction. He has also been 
referred to orthopedic surgeon in view of the bony lytic lesions.
DISCUSSION
Our child had unilateral café-au-lait spots and PFD without any 
endocrine manifestations. PFD is a distinctive finding in affected 
individuals. It refers to cases in which multiple skeletal sites 
are affected and it often predominates on one side of the body 
(unilateral) [5] which was similar in our case. The prevalence of 
café-au-lait spots in MAS was estimated to range from 53.1% to 
92.5% [3]. These lesions are often limited to one side of the body, 
which usually corresponds to the side with bone involvement and 
generally do not cross the midline. Moreover, they are typically 
arranged in a segmental pattern, which follows the developmental 
lines of Blacschko [6].
Diagnosis of MAS is usually established on clinical grounds. 
Plain radiographs are often sufficient to make the diagnosis of FD. 
The explanation which is widely accepted but remains unproven 
for the lack of vertical transmission, along with the observation 
that the skin and bone lesions tend to lateralize, is that the disease 
results from postzygotic mutations; therefore, the patients 
are referred to as somatic mosaics - the mosaicism could explain 
the varied clinical picture of those with this syndrome [7], and 
more so, a negative result from readily available (but unaffected) 
tissue does not exclude the presence of the mutation.
The most important aspect of genetics is counselling of 
families to assure that there is no vertical transmission of the 
disease, and therefore, parents need not feel “responsible,” and 
patients can be assured that they will not transmit the disease 
to their offspring [8]. However, several laboratory studies 
should be conducted during the follow-up period to investigate 
for any of the endocrinological dysfunction, the most common 
being gonadotropin-independent precocious puberty, also 
hyperthyroidism [10], hypercortisolism [11], and/or pituitary 
adenomas-secreting GH and/or prolactin [12]. Hypophosphatemic 
osteomalacia has also been reported [13].
No specific medications are available to treat the bone 
manifestations of MAS. Antiresorptive agents (e.g., alendronate 
and its congeners [bisphosphonates]) are being evaluated for this 
indication and have great palliative value owing to their pain-
controlling attributes in this disease. The precocious puberty 
of MAS generally does not respond to gonadotropin-releasing 
hormone (GnRH) agonists, and short-acting aromatase inhibitors 
have had limited effectiveness. Inconsistent results have been 
reported with bromocriptine, cabergoline, octreotide, or a 
combination of these. Pegvisomant, a GH receptor antagonist, 
is a possibility, though it has not been specifically evaluated 
for the treatment of MAS with GH pathology [14]. There are 
no known environmental, ethnic, or geographic risk factors for 
the development of MAS. So far, all cases of MAS are sporadic. 
Symptoms begin during childhood, though in some cases, the 
disease is clinically silent and is discovered on routine radiographs 
obtained for an unrelated reason [15]. The history and the physical 
examination can vary based on a specific person’s syndrome.
CONCLUSION
MAS is a multisystemic condition with a host of variable 
presentations. Diagnosis and treatment of this syndrome require 
a high index of suspicion in any patient with characteristic café-
au-lait spots and endocrine dysfunction or pathologic fractures. 
No measures are available to prevent MAS; however, appropriate 
care must be taken for fracture prevention in patients with severe 
PFD.
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